NCT05879484 2025-07-10
Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn